1h Free Analyst Time
Bioverativ Inc (BIVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technology for the treatment of hemophilia A; and Alprolix, which comprises recombinant coagulation factor IX engineered using Fc fusion technology for the treatment of hemophilia B. The company’s pipeline encompasses investigational candidates for the treatment of cold agglutinin disease, hemophilia A, beta thalassemia sickle cell disease, hemophilia B, and Sickle cell disease. Bioverativ sells its products in the US, the European Union (EU), New Zealand, Canada, Australia, Japan, Switzerland, Iceland, Liechtenstein, and Norway. Bioverativ is headquartered in Waltham, Massachusetts, the US.
Bioverativ Inc Key Recent Developments
Feb 13, 2018: Bioverativ Reports Fourth Quarter and Full Year 2017 Performance
Oct 26, 2017: Bioverativ Reports Third Quarter 2017 Performance
Aug 02, 2017: Bioverativ Reports Second Quarter 2017 Performance
Jul 06, 2017: New Data to be Presented at ISTH Underscore Bioverativ’s Commitment to Advance Hemophilia Care
May 15, 2017: Bioverativ Appoints Geno J. Germano to Company’s Board of Directors
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company- Bioverativ Inc - Key Facts
- Bioverativ Inc - Key Employees
- Bioverativ Inc - Key Employee Biographies
- Bioverativ Inc - Major Products and Services
- Bioverativ Inc - History
- Bioverativ Inc - Company Statement
- Bioverativ Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
Section 2 – Company Analysis
- Company Overview
- Bioverativ Inc - Business Description
- R&D Overview
- Bioverativ Inc - Corporate Strategy
- Bioverativ Inc - SWOT Analysis
- SWOT Analysis - Overview
- Bioverativ Inc - Strengths
- Bioverativ Inc - Weaknesses
- Bioverativ Inc - Opportunities
- Bioverativ Inc - Threats
- Bioverativ Inc - Key Competitors
Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
- Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
- Bioverativ Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
- Feb 13, 2018: Bioverativ Reports Fourth Quarter and Full Year 2017 Performance
- Oct 26, 2017: Bioverativ Reports Third Quarter 2017 Performance
- Aug 02, 2017: Bioverativ Reports Second Quarter 2017 Performance
- Jul 06, 2017: New Data to be Presented at ISTH Underscore Bioverativ’s Commitment to Advance Hemophilia Care
- May 15, 2017: Bioverativ Appoints Geno J. Germano to Company’s Board of Directors
- May 03, 2017: Bioverativ Reports First Quarter 2017 Results
- Apr 10, 2017: Bioverativ Appoints Tim Harris Executive Vice President, Research and Development
- Mar 02, 2017: Anna Protopapas to Join Bioverativ Board of Directors
- Mar 02, 2017: Anna Protopapas to Join Bioverativ Board of Directors
Section 6 – Appendix
- Methodology
- Ratio Definitions
- About
- Contact
- Disclaimer
List of Tables
- Bioverativ Inc, Key Facts
- Bioverativ Inc, Key Employees
- Bioverativ Inc, Key Employee Biographies
- Bioverativ Inc, Major Products and Services
- Bioverativ Inc, History
- Bioverativ Inc, Other Locations
- Bioverativ Inc, Subsidiaries
- Bioverativ Inc, Key Competitors
- Bioverativ Inc, Ratios based on current share price
- Bioverativ Inc, Annual Ratios
- Bioverativ Inc, Annual Ratios
- Bioverativ Inc, Annual Ratios
- Bioverativ Inc, Interim Ratios
- Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
- Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
- Bioverativ Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
List of Figures
- Bioverativ Inc, Performance Chart (2013 - 2017)
- Bioverativ Inc, Ratio Charts
- Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
- Bioverativ Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Samples
LOADING...
Companies Mentioned
A selection of companies mentioned in this report includes:
- Pfizer Inc
- Novo Nordisk AS
- Bayer AG
